Nora Nganyewo Nghochuzie

Nora Nganyewo Nghochuzie

Auto-generated profile, based on publicly available information

Nora Nganyewo Nghochuzie

Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The Gambia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2020 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
NNNora Nganyewo Nghochuzie
Nora Nganyewo Nghochuzie
COCharles Ochieng' Olwal
Charles Ochieng' Olwal
AUAniefiok John Udoakang
Aniefiok John Udoakang
LALucas Naam-Kayagre Amenga-Etego
Lucas Naam-Kayagre Amenga-Etego
AAAlfred Amambua-Ngwa
Alfred Amambua-Ngwa
Malaria remains a major global health burden, killing hundreds of thousands annually, especially in sub-Saharan Africa. In 2019, a Phase IV Expanded Programme on Immunization (EPI)-linked malaria vaccine implementation was underway. However, in December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with many clinical, epidemiological, and biological parallels to malaria, was reported in Wuhan, China. COVID-19 is spreading rapidly, and, as of the 3rd of June, 2020, more than 382,507 persons had died from COVID-19. Children under 5 years who suffer high malaria-attributable mortalities are largely asymptomatic for COVID-19. Considering that the malaria burden is highest in low-income tropical countries with little capacity to fund malaria control and eradication programs, the fight against malaria in these regions is likely to be hampered. Access to healthcare has generally been limited, while malaria interventions, such as seasonal malaria chemotherapy and distribution of insecticide-treated bed nets, have been suspended due to lockdowns. Likewise, the repurposing of antimalarials for treatment of COVID-19 shared symptoms and the shift in focus from the production of malaria rapid diagnostic tests (RDTs) to COVID-19 RDTs is a cause for concern in malaria-endemic regions. Children are less affected by the COVID-19 pandemic compared to the elderly. However, due to the fears of contracting SARS-CoV-2, the elderly who are worst affected by COVID-19 may not take children for malaria medication, resulting in high malaria-related mortalities among children. COVID-19 has disproportionately affected developed countries, threatening their donation capacity. These are likely to thwart malaria control efforts in low-income regions. Here, we present perspectives on the collateral impact of COVID-19 on malaria, especially in Africa.

11 January 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MRManuel Ritter
Manuel Ritter
WNWinston Patrick Chounna Ndongmo
Winston Patrick Chounna Ndongmo
ANAbdel Jelil Njouendou
Abdel Jelil Njouendou
NNNora Nganyewo Nghochuzie
Nora Nganyewo Nghochuzie
LNLucy Cho Nchang
Lucy Cho Nchang
AHAchim Hoerauf
Achim Hoerauf
The filarial nematode Mansonella perstans is endemic throughout Africa, northern South America and the Caribbean. Interestingly, M. perstans-infected individuals present no distinct clinical picture associated with certain pathology. Due to its relatively silent nature, research on this tropical disease has been neglected, especially M. perstans-driven immune responses. A hindrance in obtaining data on M. perstans-specific responses has been the inability to obtain adult worms since their habitats in serous cavities are difficult to access. Thus, in this study, for the first time, we used Mansonella perstans worm antigen extract as stimulant to obtain filarial-specific recall and immunoglobulin responses from M. perstans microfilaremic individuals (Mp MF+) from Cameroon. Moreover, systemic immune profiles in sera and immune cell composition in peripheral blood from Mp MF+ and amicrofilaremic individuals (Mp MF-) were obtained. Our data reveal that Mp MF+ individuals showed significantly reduced cytokine (IL-4, IL-6 and IL-12p70) and chemokine levels (IL-8 and RANTES), but significantly higher MIP-1β as well as increased M. perstans-specific IgG4 levels compared to Mp MF- individuals. In contrast, upon re-stimulation with worm antigen extract, IFN-γ, IL-13, IL-10 and IL-17A secretion was enhanced in cell cultures from Mp MF+ individuals when compared to those from cultures of healthy European individuals. Moreover, analysis of immune cell composition in peripheral blood from Mp MF+ individuals revealed increased type 2 helper T (Th2), natural killer (NK), regulatory B and T cell (Breg and Treg) subsets but decreased type 1 regulatory T (Tr1) cells. In summary, this study deciphers for the first time, M. perstans-specific immune responses using worm antigen extract and shows that patent M. perstans infections have distinct Th2, Breg and Treg subsets accompanied with reduced systemic innate and adaptive immune responses and dominant filarial-specific IgG4 levels. Although there are approximately 114 million infected people with Mansonella perstans, there is a paucity of information about how this filarial nematode affects the host's immune system. M. perstans currently poses a potential risk to 581 million people throughout Africa and for many years infections were considered to be nonpathogenic because individuals presented undefined and non-distinct clinical symptoms. Due to lack of treatment and the potential consequences on co-infections, M. perstans infections are however, regarded as a public health problem in endemic areas. The long-lasting co-existence of the worm with its human host implies potential immune-modulatory properties that may also affect responses to other infections; an aspect that has not been well addressed. In this study, we were interested in determining whether M. perstans-infected patients from Cameroon show a distinct immunological profile. In addition, we applied for the first time M. perstans worm antigen extract in order to test its re-stimulation capacity on cells isolated from M. perstans-microfilaremic individuals. Overall this study shows that M. perstans-microfilaremic individuals have a distinct immune profile, which is characterized by increased Th2 and regulatory cell populations concomitant with reduced systemic cytokine/chemokine and increased filarial-specific IgG4 levels. In addition, the M. perstans-specific down-regulation of immune responses might be an explanation for the increased susceptibility and worsened disease course of HIV, tuberculosis and malaria in M. perstans endemic regions.

14 April 2026 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
NDNdey Fatou Drammeh
Ndey Fatou Drammeh
FBFatoumata Bojang
Fatoumata Bojang
NNNora Nghochuzie Nganyewo
Nora Nghochuzie Nganyewo
AJAminata Seedy Jawara
Aminata Seedy Jawara
BMBaboucarr Manneh
Baboucarr Manneh
AAAlfred Amambua-Ngwa
Alfred Amambua-Ngwa
Sustained antimalarial drug use against Plasmodium falciparum has often resulted in drug resistance and the selection of associated genetic markers in malaria endemic populations. The genetic markers of resistance to legacy drugs like chloroquine persist in The Gambia. This study assesses the effect of these legacy drug-resistance genomic backgrounds on in vitro responses to antimalarial drugs in The Gambia. P. falciparum drug-resistance genotypes at pfcrt, pfmdr1, pfdhfr, pfdhps, and pfkelch13 genes was determined from amplicon sequencing of 364 isolates. In vitro 50% growth inhibitory concentrations (IC50s) were determined for 68 isolates to chloroquine, dihydroartemisinin, lumefantrine, mefloquine, piperaquine, and amodiaquine. In vitro response to drugs was assessed for parasite groups with different major multi-locus drug-resistance genetic backgrounds. Two main multi-locus drug-resistance backgrounds driven by pfcrt haplotypes (CVMNK/CVIET) were observed. CVIET (62%) isolates were resistant to chloroquine, whereas CVMNK was less sensitive to mefloquine and dihydroartemisinin. The pfmdr1 NFD haplotype was 60% prevalent, with 184F at 67%. Infections with the CVIET-NFD combination (31.7%) had the highest chloroquine IC₅₀s. Pfdhfr S108N (98%) and pfdhps A437G (85%) mutants were highly prevalent. No validated pfkelch13 resistance mutations were detected. Artemisinin-based combination therapies remain effective in The Gambia, supported by the absence of pfkelch13 mutations. However, reversion to chloroquine sensitivity tends to result in reduced sensitivity to artemisinin-based combination therapy drugs. These genotype-phenotype dynamics need continuous monitoring to guide drug interventions towards malaria elimination.